iShares US SmallCap Equity Factor

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Tapestry CEO states group focuses on organic growth

Abacus Wealth Increases Stake in Sterling Infrastructure as Earnings Beat Expectations

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

nVent Announces Stock Repurchase Authorization

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Vienna Universal Pension Increases Jabil Stake to 13th Largest Holding; Jabil Beats Earnings Expectations

Kalshi Partners with Interactive Brokers to Integrate Prediction Markets into Trading Platform

Interactive Brokers Expands Prediction Markets to Unify Access to Kalshi, CME, and ForecastEx

Valeo Financial Advisors Acquires $571k of Flex Ltd. Stock in Q4

Mira AI Simplifies Information Extraction Process for Tapestry

nVent Electric Executive Obtained Stock Options

Flex Executives Sell Shares

nVent Electric plc CTO Reduced Company Shares

Martha Claire Bennett exercises stock options and sells shares

Telsey Advisory Maintains Buy Rating on Tapestry

Sterling Infrastructure Updates Its Stock Issuance Shelf Registration

Truist Financial Corp Cuts Stake in Jabil

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

InMed Pharmaceuticals

NextNRG

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Meiwu Tech

CN Energy

Generation Income Properties

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

MetaVia

SGHT

SMLF

<p>Sight Sciences, Inc. (NASDAQ:SGHT) has received a consensus recommendation of 'Hold' from nine analysts. The average target price is $8.31, with one sell, three hold, and five buy ratings. Recent insider sales include Jeremy B. Hayden selling 13,761 shares and CTO David Badawi selling 8,168 shares. The stock is currently valued at $5.20, up 6.1%, with a market cap of $282.93 million. The company reported a quarterly EPS of ($0.24), missing estimates.</p>

Market Beat

Sight Sciences

ISHRS Russ 2000 Growth

SPDR S&P Health Equip

iShares US Medical Devices

UBS Group AG

Citigroup

Manulife Financial

MANULIFE-S

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of "Hold" from Analysts

FNCL

<p>Shares of the iShares US Small-Cap Equity Factor ETF (SMLF) have entered oversold territory, trading as low as $73.82 per share. The Relative Strength Index (RSI) for SMLF is at 29.3, indicating oversold conditions, compared to the S&P 500's RSI of 33.9. This may suggest that heavy selling is exhausting, presenting potential buying opportunities. SMLF's 52-week range is $53.49 to $80.72, with the last trade at $74.60, reflecting a 2% decline on the day.</p>

iShares US SmallCap Equity Factor(SMLF.US)

Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of "Hold" from Analysts

Shares of SMLF Now Oversold